Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Nu

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person* Taub Rebecca					2. Issuer Name and Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS, INC. [MDGL]								heck a	all applic	able) r	g Pers		ner	
(Last) (First) (Middle) C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2018								X Officer (give title below) Other (specify below) Chief Medical Officer, EVP R&D						
(Street) WEST CONSHO	OHOCKEN (S		19428 (Zip)	4.									Individue)	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non-D	Derivativ	e Se	curities	s Ac	quired, [Disp	osed o	f, or Be	neficia	lly C	wned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Code (In	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)				4 and Securitie Benefici Owned F		es Form ally (D) (Following (I) (I		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D) Pi		- 1-	Reported Transaction(s) (Instr. 3 and 4)				(111501.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code	action (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		expiration vate	Title	Amoun or Numbe of Shares							
Stock Option (Right to Buy)	\$124.45	03/01/2018		A		38,000		(1)	0	3/01/2028	Common Stock	38,000		\$0	38,000)	D		

Explanation of Responses:

1. The option vests as to 25% of the shares on the first anniversary of the date of grant (March 1, 2019) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date.

/s/ Michael Lawhead, as

attorney-in-fact for Rebecca 03/05/2018

<u>Taub</u>

** Signature of Reporting Person Da

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.